Drug Trial Radar · NCT07874269
MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
205
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Jumraini TammasseAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, controlled clinical trial evaluates the effectiveness and safety of combined mesenchymal stem cell (MSC) secretome and repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute ischemic stroke. Participants will be randomized to either an intervention group receiving intravenous MSC secretome combined with high-frequency ipsilesional rTMS or a control group receiving placebo infusion and sham rTMS. The intervention is administered once weekly for 8 weeks. The primary outcome is change in motor function measured using the Fugl-Meyer Motor Scale. Secondary outcomes include changes in quantitative electroencephalography biomarkers, including sensorimotor rhythm, delta-theta-to-alpha-beta ratio, and beta coherence, as well as spasticity assessed using the Modified Ashworth Scale and treatment-related adverse events.
Conditions
- Ischemic Stroke
Interventions
Mesenchymal Stem Cell-Derived SecretomeBiological
Intravenous mesenchymal stem cell-derived secretome at a dose of 1.5 × 10\^9 particle equivalents is administered once weekly for 8 weeks. Administration is performed through intravenous access using aseptic technique by trained medical personnel, with monitoring for possible adverse events during and after administration.
Active Repetitive Transcranial Magnetic StimulationDevice
High-frequency repetitive transcranial magnetic stimulation is delivered at 10 Hz, 1500 pulses per session, at 80% of the resting motor threshold over the ipsilesional primary motor cortex (M1). Treatment is administered once weekly for 8 weeks.
0.9% Sodium Chloride PlaceboDrug
Participants in the control group receive an intravenous infusion of 0.9% sodium chloride as placebo according to the same treatment schedule as the active secretome intervention.
Sham Repetitive Transcranial Magnetic StimulationDevice
Sham repetitive transcranial magnetic stimulation is performed using procedures designed to resemble active rTMS without delivering therapeutic stimulation. Sham sessions follow the same treatment schedule as the active rTMS sessions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Fugl-Meyer Motor Scale ScoreTime frame: Baseline to week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Inggit Medical Centre
Makassar, South Sulawesi, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.